Mushrooms: Insomnia Trigger Or Sleep Aid?

Sleep is a crucial part of our lives, and insomnia is a common problem that affects many people. While there are many potential causes of insomnia, one factor that has been the subject of interest and debate is the consumption of mushrooms, specifically psychedelic mushrooms. Psilocybin, the active compound in psychedelic mushrooms, has been found to alter consciousness and induce hallucinations, but does it also cause insomnia? This question has sparked curiosity and research, with some individuals even experimenting with mushroom coffee as a potential solution for better sleep. So, let's delve into the relationship between mushrooms and sleep to understand if mushrooms are a culprit or a cure when it comes to insomnia.

Psilocybin and psilocin are the main psychoactive components of mushrooms

Psilocybin mushrooms, commonly known as magic mushrooms or shrooms, are a type of hallucinogenic mushroom. They are a polyphyletic informal group of fungi that contain the prodrug psilocybin, which turns into the psychedelic psilocin upon ingestion. Psilocybin is a chemical found in magic mushrooms that gives a psychedelic experience. Psilocybin is the key ingredient in magic mushrooms, and when it is taken, it is converted in the body to psilocin, which is the chemical with psychoactive properties.

The total potency varies greatly between species and even between specimens of a species collected or grown from the same strain. Because most psilocybin biosynthesis occurs early in the formation of fruit bodies or sclerotia, younger, smaller mushrooms tend to have a higher concentration of the drug than larger, mature mushrooms. In general, the psilocybin content of mushrooms is quite variable, ranging from almost nothing to 2.5% of the dry weight, and depends on species, strain, growth and drying conditions, and mushroom size. Cultivated mushrooms have less variability in psilocybin content than wild mushrooms. The drug is more stable in dried than fresh mushrooms; dried mushrooms retain their potency for months or even years, while mushrooms stored fresh for four weeks contain only traces of the original psilocybin.

Psilocybin's somatic effects have been corroborated by several early clinical studies. A 2005 magazine survey of clubgoers in the UK found that over a quarter of those who had used psilocybin mushrooms in the preceding year experienced nausea or vomiting, although this was caused by the mushroom rather than psilocybin itself. In one study, the administration of gradually increasing dosages of psilocybin daily for 21 days had no measurable effect on electrolyte levels, blood sugar levels, or liver toxicity tests. The onset of action of psilocybin taken orally is 0.5 to 0.8 hours (30–50 minutes) on average, with a range of 0.1 to 1.5 hours (5–90 minutes). Peak psychoactive effects occur at about 1.0 to 2.2 hours (60–130 minutes).

Psilocybin increases brain activity in regions activated during dream sleep

Psilocybin is a chemical found in magic mushrooms that induces a psychedelic experience. Psilocybin and its metabolite, psilocin, are the main psychoactive components of psychedelic mushrooms. Psilocybin acts as an agonist of serotonergic 5-HT1A and 5-HT2A/C receptors in the central nervous system, leading to altered states of consciousness.

Research has shown that psilocybin increases brain activity in regions associated with dreaming and emotion. Brain imaging studies have revealed increased amplitude or "volume" of activity in brain regions typically activated during dream sleep. These regions are part of the brain's ancient emotion system. Psilocybin also facilitates a state of "expanded" consciousness, enhancing the breadth of associations and cognition.

The increased brain activity during psilocybin use has been compared to the neuronal activity observed during REM sleep. Studies have shown that psilocybin increases brain function in areas associated with memory and emotion, similar to the patterns observed during dreaming. This leads to the belief that psilocybin places individuals into a ""waking dream state" or a "waking REM state."

Additionally, psilocybin research reveals decreased activity in certain brain regions, such as the thalamus, prefrontal cortex, posterior cingulate cortex, and anterior cingulate cortex. These findings provide insights into the functionality of these brain regions and their role in dreaming and consciousness.

While psilocybin has been shown to increase brain activity in dream-related regions, it is important to note that it also disrupts normal sleep patterns. Studies have found that psilocybin and psilocin can delay REM onset and reduce the time spent in deep REM sleep, suggesting that they push the brain into a wakeful, dream-like state.

Overall, the effects of psilocybin on brain activity and sleep patterns provide valuable insights into the potential therapeutic benefits of psychedelics and their ability to induce a dream-like state during wakefulness.

Serotonergic psychedelics increase wakefulness and inhibit REM and NREM sleep

Psilocybin, the chemical found in magic mushrooms, induces a psychedelic experience that alters consciousness. Psilocybin's metabolite, psilocin, acts as a partial agonist of 5-HT2A receptors, disrupting neural dynamics and functional networks across the brain. This disruption results in altered perception, cognition, and emotions, leading to long-term positive changes in well-being and mood.

Research has shown that serotonergic psychedelics, including LSD, dimethyltryptamine (DMT), and mescaline, cause sleep alterations. Specifically, they increase wakefulness and inhibit REM and NREM sleep. For example, psilocin, the active metabolite of psilocybin, delays REM sleep onset and reduces NREM sleep maintenance. This disruption in sleep architecture is likely due to the serotonergic system's role in regulating sleep and wakefulness states.

The serotonin system's role in sleep-wake control is complex. Serotonergic neurons are more active during wakefulness, and serotonin is part of the monoaminergic ascending arousal system that maintains wakefulness. Additionally, 5-HT2A receptor agonists have been shown to have a sleep-suppressing effect, while antagonists increase sleep depth and maintenance. This knowledge has led to the exploration of psychedelics in the treatment of insomnia.

Furthermore, the effects of psilocybin on neurogenesis and sleep may be dose- and time-dependent. Different doses or administration timings could impact the expression of slow-wave sleep (SWS). For instance, Ayahuasca, a traditional psychedelic drink containing DMT, increased EEG slow-wave activity during sleep, while psilocybin suppressed it in the first cycle of NREM sleep. These differences highlight the complex nature of serotonergic psychedelics' impact on sleep and the need for further research.

Psychedelics cause temporary ego dissolution and alter consciousness

Psilocybin, the chemical found in magic mushrooms, can cause alterations in perception, cognition, and emotions, leading to altered states of consciousness. This is due to its action on serotonergic 5-HT1A and 5-HT2A/C receptors in the central nervous system. Psilocybin can induce a state of "expanded" consciousness, increasing the breadth of associations and causing a sense of "ego dissolution".

Psychedelics, including psilocybin, have been shown to alter many aspects of human experience, such as sense perception, emotion, cognition, and the perception of time and space. However, their most intriguing effect is perhaps the temporary "ego dissolution" they induce, which is a profound alteration of one's ordinary sense of self or "I". Users often report a diminished sense of being a distinct self, separate from the rest of the world, during intoxication. This can be described as a loss of subjective self-identity or a sense of union with an ultimate reality, also known as "cosmic consciousness".

The concept of "ego death" or "ego dissolution" has been explored in various fields, including romantic movements, transpersonal psychology, and Buddhism. It is often associated with the idea of enlightenment, where one lets go of their sense of self and falls into a void of non-existence. This experience can be facilitated by psychedelics, which disrupt the usual frontal-posterior coupling that underlies self-awareness.

Neuroimaging investigations have begun to identify the neural correlates of these changes in consciousness, providing insight into the effects of psychedelics on the brain. The variability and complexity of psychedelic experiences pose challenges in understanding these states, but progress has been made in charting the phenomenology of these altered states of consciousness.

Sleep deprivation is linked to the onset of serious neurodegenerative disorders

Sleep is essential for overall health and well-being, and disruptions to sleep can have far-reaching consequences. Sleep deprivation has been linked to the onset of serious neurodegenerative disorders, highlighting the critical role of sleep in maintaining brain health.

Neurodegenerative disorders are a group of diseases characterized by progressive deterioration of the nervous system, leading to problems with movement, cognition, and behaviour. Examples of such disorders include Alzheimer's disease, Parkinson's disease, and dementia. Research has revealed a complex and bidirectional relationship between sleep deprivation and neurodegenerative disorders.

In human studies, brain imaging techniques have shown that chronic sleep deprivation can lead to changes in brain volume, indicating potential cell loss and neurodegeneration. Animal studies have also demonstrated that sleep deprivation can cause neural injury and increased stress levels, impacting the circadian rhythm and metabolic processes.

Additionally, insomnia, a common sleep disorder characterized by difficulty falling asleep, maintaining sleep, or experiencing non-restorative sleep, is a known risk factor for neurodegenerative disorders. Insomnia is often associated with Alzheimer's disease, as it leads to increased deposition of β-Amyloid and hyper-phosphorylated Tau proteins in the brain, contributing to the progression of the disease.

Furthermore, sleep plays a crucial role in clearing toxic proteins from the brain. Sleep disruptions, such as those caused by untreated obstructive sleep apnea (OSA), can increase the risk or accelerate the onset of dementia or mild cognitive impairment (MCI). This is supported by studies showing that a majority of patients with MCI experience sleep complaints, including increased arousals during slow-wave sleep and difficulty maintaining sleep.

While the exact mechanisms are still being explored, the available evidence suggests that sleep deprivation and disorders are not just symptoms of neurodegenerative disorders but may also contribute to their onset and progression. Therefore, recognizing and treating sleep disorders may be a crucial aspect of managing and potentially delaying the progression of these serious conditions.

Frequently asked questions